GAUDIUMIVFBSEGaudium IVF and Women Health LtdHighNeutral
Announced Thu, 28 May · 20:18 IST

Standalone and Consolidated Audited Financial Results for the Quarter and Year ended March 31, 2026

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

GAUDIUMIVF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹116.79
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.8-3.8-5.7-7.6-9.4-9.5-6.9-5.1
Up moveDown movePending
AI summary

Gaudium IVF reported strong FY26 results with consolidated revenue growing 47.5% to ₹10,435.70 Lakhs from ₹7,072.40 Lakhs. Profit after tax increased 27.7% to ₹2,448.85 Lakhs from ₹1,917.73 Lakhs. Q4 standalone revenue was ₹2,216.60 Lakhs with PAT of ₹773.14 Lakhs. The company completed its IPO in February 2026, raising ₹9,000.08 Lakhs through fresh issue, though ₹8,131.20 Lakhs of proceeds remain unutilized as of March 2026. Trade receivables increased significantly to ₹5,337.93 Lakhs from ₹3,286.72 Lakhs, while finance costs more than doubled to ₹349.16 Lakhs. Auditors issued unmodified (clean) opinions for both standalone and consolidated results.

Likely market impact

The company delivered robust growth with revenue and profit both expanding significantly. However, the large unutilized IPO proceeds and rising receivables warrant monitoring. The clean audit opinion is positive for investor confidence, though the doubling of finance costs and high receivables growth suggest increased financial leverage and potential collection risks.